PerkinElmer has launched the research use only BioQule™ NGS System for next-generation sequencing (NGS) library preparation to help produce libraries that yield reliable, reproducible results in a variety of applications requiring genomic analysis.
Recent Media Coverage
Read recent articles about PerkinElmer below. Clicking a headline will take you to the publication’s website for the full article.
Arvind Kothandaraman, managing director of specialty diagnostics at PerkinElmer, discusses how to build a global surveillance model for pandemic preparedness through a three-pronged approach in this thought leadership blog.
Arvind Kothandaraman, managing director for specialty diagnostics at PerkinElmer, explains the value of new single-cell technologies, including the HIVE™ scRNAseq Solution from Honeycomb Biotechnologies, that can help provide personalized treatment and drive better health outcomes.
From comprehensive disease surveillance to better hiring and retention practices, our Managing Director of Specialty Diagnostics Arvind Kothandaraman outlines strategies clinical labs will use to meet the challenges of future viral outbreaks in this contributed article.
Lyme disease has been a nationally recognized condition in the United States since 1991 and is the most common vector-borne illness in North America and Europe. Scientific Affairs Manager Maite Sabalza and Scientific Affairs Associate Ilana Heckler at EUROIMMUN, a PerkinElmer company, demystify Lyme disease’s transmission and diagnosis while sharing future perspectives.
In this article, Toby Astill, Global Market Manager for Cannabis and Hemp at PerkinElmer, discusses how smart data management can drive better, faster and earlier decision making around quality and compliance.
Peter Wrighton-Smith, CEO of Oxford Immunotec, shares insights about the values of T cells in the immune system and how they help evaluate individuals’ immune responses.
In this article, PerkinElmer’s R&D Manager specializing in food and dairy, Wopke Beukema, identifies five trends changing the dairy industry as well as some ways that processors can capitalize on them to “add new firepower to their value and quality.”
In the second part of this two-part series, Dr. Christian Landles, senior research associate in neurodegenerative diseases at UCL Queen Square Institute of Neurology, discusses the development of therapies for rare diseases such as HD and how technologies such as those offered by PerkinElmer can help develop a more targeted biomarker and drug discovery approach to counter mutant huntingtin protein to improve treatment options for people with HD.
In the first part of this interview series, Dr. Christian Landles, senior research associate in neurodegenerative diseases at UCL Queen Square Institute of Neurology, highlights recent progress in understanding Huntington’s Disease (HD) as well as the importance of HD biomarker characterization and identification. PerkinElmer is proud to be supporting Dr. Landles’ research with its custom labelling service utilizing PerkinElmer’s AlphaLISA and HTRF technologies, microplates, and EnVision plate reader, generously supported by grants from the CHDI Foundation and UK Dementia Research.
Projects underway in the United States and UK are evaluating the use of whole-genome sequencing (WGS) as a screening tool for healthy newborns. In this article, Madhuri Hegde, SVP and chief scientific officer of global laboratory services at PerkinElmer, describes the value of WGS as a lifelong medical reference for families and provides details on PerkinElmer’s cord blood banking business, ViaCord.
In this interview with the Dairy Reporter, PerkinElmer’s senior manager R&D, food segment, Wopke Beukema introduces how the streamlined LactoScope 300 platform detects adulterants in raw and processed milk to ensure quality and safety.
In this article, PerkinElmer’s EMEAI regional segment leader environmental, Luca Piatti, shares deep insights about microplastics, some recent research projects on water pollution enabled by PerkinElmer’s technologies, and what the future goals of microplastics research are.
Human induced pluripotent stem cells (iPSCs) are uniquely positioned to revolutionize the fields of gene therapy and regenerative medicine. In this article written by Amanda Haupt, senior scientist and R&D project manager at Horizon Discovery, a PerkinElmer Company, she shares with us the importance of maintaining a reliable and consistent iPSC culture and the benefits of gene editing technologies for progressing therapeutic iPSCs.
In this article coauthored by PerkinElmer’s Madhuri Hegde, Ilana Heckler and Azadeh Bojmehrani, the three experts illustrate how genetic parameters are now an integral part of routine autoimmune diagnostics.
EUROIMMUN Scientific Affairs Manager Maite Sabalza discusses the importance of pre-vaccination screening for dengue vaccines and the role that local laboratories in Puerto Rico are playing in helping more children and adolescents gain access to them.
SIRION Biotech, a PerkinElmer Company, has partnered with the Center for Genomic Regulation (CRG) in Barcelona, Spain to develop adeno-associated virus (AAV) vectors for type 1 and 2 diabetes.
In Part 2 of this rare disease series, PerkinElmer’s Amanda Jones, Kyoko Kushiro, Anis Khimani and Ryan Donnelly share expert insights on rare disease therapeutics and research.
In the first part of a two-part rare disease interview, Madhuri Hegde, senior vice president and chief scientific officer, discusses the hurdles in rare disease diagnostics and how recent advances in genomic and molecular testing have improved the diagnostic process.
In this interview with PerkinElmer’s Strategy Leader for Biotherapeutics Drug Discovery Glen Molotnikov and General Manager of Applied Genomics James Atwood, the two experts shed lights on the Company’s JANUS G3 Assay Development workstation as well as the HIVE scRNAseq Solution for single-cell isolation and analysis.
In this conversation at the meeting of the Society for Laboratory Automation and Screening (SLAS), Alan Fletcher, senior vice president of life sciences at PerkinElmer, introduces how the Company has been transforming its portfolio in the past year through a number of acquisitions.
The EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) (RUO) was recently cited by the U.S. Centers for Disease Control and Prevention as part of a two-step testing algorithm guidance for pre-vaccination screening for Dengvaxia, which is used to help prevent future dengue disease.
PerkinElmer’s Senior Strategy Leader, Pharma Development, Life Sciences Anis H. Khimani shares how automated workflows can enhance the drug discovery output and alleviate big data challenges.
Sukhvinder Nicklen, PerkinElmer market development leader, outlines the potential of whole genome sequencing for newborn screening to detect a wide range of genetic disorders.
The UK government has pledged £5 billion towards health-related R&D, including a pilot programme for genome sequencing in newborns. Chris Hughes, managing director of PerkinElmer UK & Ireland, discuses how whole genome sequencing can benefit future generations.
The COVID-19 pandemic has taught us the importance of jointly developing diagnostics tools and technologies for the betterment of the entire world. Three PerkinElmer thought leaders share their perspectives on what are expected in 2022, including increasing collaboration, focusing on T cell response and advancing antibody measurement.
In 2022, Dr. Madhuri Hegde predicts that there will be increased interest and applications of multiomics in healthcare. In a recent article for Labcompare, Dr. Hegde, our SVP and Chief Scientific Officer for Global Lab Services, explains further how multiomics will continue to improve our understanding of the human genome and with broad applications, benefit global public health for years to come.
In this article, Gerlinde Wita, global market manager, materials, energy & petrochem at PerkinElmer, discusses the problems that the polymer analysis industry is looking to address and the solutions to them.
Arvind Kothandaraman, managing director, specialty diagnostics at PerkinElmer, uncovers the design of multianalyte tests that help conserve precious resources and differentiate COVID-19, flu and respiratory syncytial virus.
Arvind Kothandaraman, managing director of specialty diagnostics, and Ishu Venkataraman, associate director of scientific affairs for EUROIMMUN US, shared their thoughts around the impact of antibody technologies and collaboration on the diagnostics landscape as we’re entering 2022.
Wheat testing solutions need to be accurate and efficient throughout the supply chain. PerkinElmer's Global Market and Portfolio Manager Wes Shadow explains how innovative testing tools and approaches can be beneficial for food processors.
The COVID-19 pandemic has brought significant changes to the R&D landscape in the past two years. PerkinElmer Managing Director of Specialty Diagnostics Arvind Kothandaraman shared his perspective on increasing collaborations, including shared online data supported by Next Generation Sequencing.
Health experts say that flu/COVID-19 combination tests could help prevent a “twindemic” this year. PerkinElmer Managing Director of Specialty Diagnostics Arvind Kothandaraman shared his insights on how health care systems can work to navigate testing in the flu season.
As sequencing remains crucial in SARS-CoV-2 surveillance, the PerkinElmer NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit v2 enables laboratories to increase sequencing throughput and make reliable variant identifications.
Discussions of laboratory innovations are oftentimes focused on automation and the other advanced technologies that optimize and accelerate the work of scientists. Controls and reagents, however, play an equally important role – if not more so – in the modern clinical lab.
The timing of this announcement is particularly opportune, as increasing knowledge and advances in WGS amongst scientists has resulted in the technology becoming increasingly affordable and effective, making its incorporation into the existing standardised newborn screening (NBS) procedures in the UK a possibility.
PerkinElmer announces the launch of its PKeye Workflow Monitor, a cloud-based platform enabling laboratory personnel to remotely manage and monitor their PerkinElmer instruments and workflows in real-time.
Mount Sinai Health System is making COVID-19 testing less invasive and more efficient for local schools, businesses and other organizations. FOX 5 recently took a look inside the lab, which also features several PerkinElmer instruments.
Arvind Kothandaraman, managing director of specialty diagnostics at PerkinElmer, shares the concept and benefits of pooling tests while describing PerkinElmer’s PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel Assay, and his take on the outlook of COVID-19 diagnostics.
PerkinElmer’s automated explorer™ G3 workstation and Opera Phenix HCS technologies will help the University of Colorado’s Anschutz Medical Campus exponentially speed up its drug discovery work around diseases such as cancer, diabetes, cardiovascular disease and Alzheimer’s.
PerkinElmer is collaborating with Honeycomb Biotechnologies on the commercial launch of the HIVE™ scRNAseq Solution for single-cell isolation and analysis. With a portable, handheld device that requires no specialized instrumentation, the solution is powering the next phase of precision health.
In this podcast episode of The Dairy Reporter, Wopke Beukema, senior manager R&D at PerkinElmer, demonstrates the upgraded IndiScope™ Solution and how it can be operated with the VR technology to offer onsite testing for milk quality and safety.
Based on EUROIMMUN’s Anti-SARS-CoV-2 QuantiVac™ ELISA (IgG) that received CE mark in November 2020, the Anti-SARS-CoV-2 S1 Curve™ ELISA (IgG) has obtained EUA from the FDA. This assay allows for the qualitative and semi-quantitative detection of IgG antibodies formed against the SARS-CoV-2 S1 antigen.
The FDA has granted EUA for PerkinElmer’s PKamp™ Respiratory SARS-CoV-2 RT-PCR Panel 1 assay, which simultaneously detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV). This will alleviate confusion from similar symptoms amid a possible "twindemic" of COVID-19 and influenza.
In this special issue of GEN, the magazine uncovers major milestones and predictions from thought leaders in biotechnology and life sciences. PerkinElmer’s Senior Vice President of Life Science Alan Fletcher and Associate Director of Scientific Affairs at EUROIMMUN, a PerkinElmer company, Iswariya Venkataraman, share their insights around personalized medicine and automated immunofluorescence microscopy.
Stability testing is able to ensure the safety and efficacy of a drug product’s shelf life. Anis H. Khimani, senior strategy leader of pharma development at PerkinElmer Life Sciences, shares insights around the importance of stability tests for small-molecule drugs and how they differ from tests of biologics.
Andrea Frapporti from Horizon Discovery, a PerkinElmer company, introduces the applications of base and prime editing in cell and gene therapy, including their differences, limitations and future developments.
Optimizing the usage of equipment and instruments is crucial for lab managers. PerkinElmer’s Carola Schmidt, global director of automated solutions, and Jim Sweeney, senior product manager, global services shared their thoughts on the management of lab assets as well as the metrics and measurement of lab efficiency.
Amar Kamath, VP and general manager of Diagnostics at PerkinElmer, and Aldo Mele, senior scientist 2 at Horizon Discovery, a PerkinElmer company, share insights on how circulating tumor DNA (ctDNA) can be a promising method of routine testing for cancer care.
Following new COVID-19 initiatives from The White House, Arvind Kothandaraman, general manager of specialty diagnostics at PerkinElmer, shares his take on what it means for the COVID-19 testing landscape.
The safety and quality of face masks are crucial in helping curb the spread of COVID-19. PerkinElmer Principal Application Scientist Kenneth Neubauer discusses how the Company’s technologies are enabling the testing of metals in hygienic face masks.
Funded by the American Society of Hematology, the Consortium on Newborn Screening in Africa (CONSA) aims to screen 10,000–16,000 babies per year over the next 5 years across Africa for sickle-cell disease. PerkinElmer is supporting the effort with donations and local training.
Madhuri Hegde, senior vice president and chief scientific officer at PerkinElmer Genomics, is featured in Clinical OMICs’ annual selection of women making their mark in precision medicine. Dr. Hegde shares her life stories and experiences that have led to her success in the field.
According to industry experts, COVID-19 may have accelerated interest in next-generation sequencing (NGS). PerkinElmer Genomics SVP and Chief Scientific Officer Madhuri Hegde comments on advances in NGS technologies and its potential applications in infectious disease diagnostics.
PerkinElmer has agreed to acquire BioLegend, a global leader of antibodies and reagents. This will be the largest transaction in PerkinElmer’s history and expand PerkinElmer’s and extend their life science franchise into new segments.
As a “variant of interest” labeled by the WHO, the lambda variant has been circulating in multiple countries. Iswariya Venkataraman, PhD, associate director of scientific affairs at EUROIMMUN, a PerkinElmer company, talks about how new variants arise in communities.
In this interview, Shripad Joshi, President of PerkinElmer India and South Asia, shares the growth strategies around the India market and how a new stream of products across segments will strengthen the Company’s position in this region.
For cancer immunotherapy, multiple gene knockouts are required to augment the properties of the immune cell used for treatment. Emily M. Anderson, a principal scientist from Horizon Discovery, a PerkinElmer company, introduces how the DNA double-strand breaks (DSBs) could have an impact.
PerkinElmer is providing its PhenoVue Cell Painting Kits to the Joint Undertaking in Morphological Profiling-Cell Painting (JUMP-CP) consortium, which is led by the Broad Institute of MIT and Harvard and focused on creating and sharing the world’s largest, public cell imaging data set.
PerkinElmer’s EUROIMMUN SARS-CoV-2 ELISA (IgG) is one of two antibody tests used by the NIH’s All of Us program, which recently published evidence of SARS-CoV-2 infections in five U.S. states earlier than had initially been reported.
Our President and CEO Prahlad Singh recently joined Jim Cramer on CNBC’s Mad Money to describe how agility and innovation continue to fuel PerkinElmer's transformation. In this interview, Prahlad talked about the Company's recent acquisitions and future opportunities in the Life Sciences and Diagnostics sectors.
Mycotoxins pose many challenges for feed and grain suppliers at every stage from harvest to final production. Mark MacBeath, Food Safety Product leader, and Wes Shadow, Global Market manager of Grain, outline the best technologies to aid mycotoxin monitoring and detection.
Can gene editing technology help transition cell-based therapies to solid tumors? Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team, looks at the potential evolution of this currently costly approach into mainstream treatment of cancer patients through the application of base editing.
E. coli O157 testing has gained more attention from food producers and processors as the demand grows rapidly. Nevin Perera, Research and Development Manager at PerkinElmer, shares his insights about the steps to take to ensure safe and efficient E. coli testing.
Standardization and validation are foundations in the selection of appropriate technology, methods, reagents and consumables. Anis H Khimani, Senior Strategy and Market Segment Leader at PerkinElmer Life Sciences, discusses how to orchestrate these factors towards a holistic outcome.
Arvind Kothandaraman, general manager of specialty diagnostics at PerkinElmer, talks about the COVID-19 passport concept and how it can be implemented to ensure safe return of in-person trade shows as the world reopens.
One takeaway from COVID-19 is that understanding the mechanisms of viral evolution can help track variants in real time. Arvind Kothandaraman, our general manager of specialty diagnostics, explains how new and emerging technologies have enabled scientists and research to identify and monitor SARS-CoV-2 mutations.
Anis H. Khimani, senior strategy and product portfolio leader for Life Sciences at PerkinElmer, talks about the innovations and challenges in advancing capabilities for protein analytics to ensure the rapid development of safe and effective biotherapeutics.
Automation has helped many labs keep pace with new and increasing demands brought on by COVID-19. In this article, our Global Director of Automated Solutions Carola Schmidt shares advice on how to setup new technology initiatives for success.
Next-generation sequencing (NGS) plays a vital role in COVID-19 surveillance. Our General Manager of NGS Michelle Fraser shares her thoughts on the latest advances in NGS technology and the global effort to track the virus and its variants.
As the demand for faster separations, better peak resolution and lower detection limits increases, more food, pharma and industrial labs are moving from high performance liquid chromatography (HPLC) to ultra-high-performance liquid chromatography (UHPLC). Jackie Trudell, Portfolio Marketing Manager Chromatography and Mass Spectrometry, discusses the benefits and key considerations in making the transition smoothly.
Cell painting allows new strategies for high-content screening (HCS) practitioners to identify new drug candidates and study mechanisms of action by taking advantage of both cellular imaging and machine learning. Alexander Schreiner, high content screening applications leader, and Martin Daffertshofer, high content screening software product manager from PerkinElmer, discuss how cell painting is helping drug discovery and the current technical limitations and challenges.
Jonathan Frampton, a Corporate Development Partner on our Horizon Discovery team talks about how base editing differs from traditional genome editing tools and the exciting advances it could help help bring about, especially in cell-based therapy discovery.
EUROIMMUN announced the SARS-CoV-2 NeutraLISA assay, a surrogate neutralization test for detecting neutralizing antibodies against SARS-CoV-2. This assay is now CE marked in over 30 countries.
Lab automation is increasingly critical for typical discovery and basic life science workflows. PerkinElmer’s executive director for science and technology David Gosalvez walks us through the key challenge for labs to adapt to modern, efficient systems that maximize the potential of instruments, time, and people.
As a new addition to the CRISPR portfolio, the CRISPR interference (CRISPRi) from Horizon Discovery, a PerkinElmer company, will enable researchers to repress genes in almost all cell lines, over any length of time and at any scale from single gene readouts to high-throughput studies.
EUROIMMUN, a PerkinElmer company, has partnered with biotechnology company Oncgnostics to jointly distribute the cervical cancer test that predicts the individual cancer risk of patients.
In part one of a two part microplastics series, Kathleen A. Young, Environmental Market Leader at PerkinElmer, shares her thoughts on how PPE has increasingly impacted our environment and the importance of standardization in detecting microplastics.
PerkinElmer launched its ONE Pesticide420™ CRM Reagent and Consumable Kit to support pesticide and mycotoxin testing in cannabis and hemp. The new kits free lab technicians from complex preparations and create a simpler workflow path to streamline a lab’s supplier mix.
PerkinElmer announced its Signals informatics platform will integrate with software from Insightful Science to expand on existing capabilities in the biologics drug discovery space, which will reduce research cycle times and accelerate biologics and vaccine development.
To develop new food products and approaches, analytical tools can be used on three crucial stages in monitoring. Wes Shadow, Grain Global Market Manager at PerkinElmer, shares his thoughts around analytical tools and the outlook of food testing.
EUROIMMUN, PerkinElmer’s subsidiary, announced the EUROPattern Microscope Live (EPML) compact immunofluorescence microscope, which is compatible with EUROLabOffice 4.0 (ELO 4.0) software for modern diagnostics.
The latest RUO solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit, extends PerkinElmer’s testing portfolio to known and unknown variants.
Prahlad Singh, President and CEO of PerkinElmer, sat down with This Week in Business on NECN to talk about the Company’s COVID-19 RT-PCR and antigen tests, and how he perceives the COVID-19 testing landscape to be as vaccines roll out.
To commemorate International Women’s Day, Nicky Xu, General Manager of Diagnostics at PerkinElmer Greater China, shared how she led the development of the COVID-19 PCR test and organized national donations as a female leader.
Masoud Toloue, Senior Vice President of PerkinElmer Diagnostics, talked with 7News in Boston about PerkinElmer’s antigen test that detects SARS-CoV-2 nucleocapsid antigen in under 15 minutes. The test is expected to play an important role in point-of-care testing located at healthcare centers, travel hubs, businesses and schools.
Horizon Discovery, a PerkinElmer company, was licensed by Rutgers University for the modular base editing system that uses RNA aptamers to position DNA modifying enzymes at genome targets. This uses a pin-point system and can enhance the therapeutic potential of genome editing.
Next-generation sequencing (NGS) is used to detect underlying molecular mechanisms and variants in multiple genes to achieve targeted treatment for cancer patients. Keith Cannon, Director of Commercial Product Management and Prabha Nagarajan, Senior Research Scientist at Horizon, a PerkinElmer company, highlight the importance and prospect of NGS initiatives.
As an addition to the PhenoVue cellular imaging reagent portfolio, PerkinElmer’s first cell painting kit completes the suite of high-content screening products and expert services to build more streamlined workflows.
Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, discusses how the emerging genetic variants of SARS-Cov-2 can impact false negative rates and the characteristics RT-PCR assays need to remain accurate.
John Rontree, Portfolio Director and Leader of Mass Spectrometry and Anis H. Khimani, senior strategy and market life sciences segment leader in life sciences at PerkinElmer share their thoughts on quantitation, automation and innovative assays in proteomics as an approach to understanding their role in complex biological systems, supporting high-throughput PCR testing environments and helping drive innovative therapeutics development for COVID-19.
Since their discovery last year, coronavirus neutralizing antibodies have been touted as possible treatments and diagnostic targets. Anis H. Khimani, Senior Strategy and Market Segment Leader at PerkinElmer and Kai Fechner, Director of International Sales and Marketing at EUROIMMUN (a PerkinElmer company), talk about what defines an ideal NAb assay.
While most Escherichia coli strains are harmless, some can cause intestinal illness in groups under higher risk. PerkinElmer’s newly launched Solus One O157 Pathogen Detection Assay provides a highly sensitive, cost effective system with an industry-leading result sample volume.
PerkinElmer announced new additions to the existing GPCR portfolio including an industry’s first GPCR TR-FRET binding assay, along with Beta-Arrestin kits and more.
A new report by PerkinElmer and MIT Technology Review Insights focuses on how leading pharma and chemical companies use AI, quantum computing and other digital technologies to innovate scientific research and elevate R&D performance.
As one of the world’s largest suppliers of laboratory and diagnostic reagents and equipment, PerkinElmer was in prime position to respond to COVID-19. As the pandemic took hold, Iswariya Venkataraman, scientific affairs manager at EUROIMMUN US, a PerkinElmer subsidiary, shares how the Company developed its now-established qualitative test to assist vaccine developers in understanding if their products elicited antibody responses, and how strong those responses were.
Dr. Sanjay Garg, Operations of Sanofi Pasteur and our own Dr. Anis H. Khimani discuss how the COVID-19-driven innovation and collaboration cycles are changing vaccine development forever.
EUROIMMUN, a PerkinElmer company, launched a Research Use Only, SARS-CoV-2 Interferon Gamma Release Assay (IGRA) to determine the activity of T-cells reactive to SARS-CoV-2.
PerkinElmer New Coronavirus Nucleic Acid Detection Kit that originally obtained FDA EUA in the spring of 2020 and is also approved for sample pooling, is now greenlighted by the FDA to test asymptomatic individuals.
Despite the hardship, silver linings can be found amidst the pandemic. Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, shares takeaways for diagnostic labs to help prevent pandemics of this magnitude in the future.
Through the acquisition of Oxford Immunotec, a leading company specialized in diagnosing infection with tuberculosis, PerkinElmer will grow its portfolio of advanced infectious disease testing solutions to include tuberculosis detection to better serve customers around the world.
Arvind Kothandaraman, PerkinElmer’s General Manager, Specialty Diagnostics, talks about trends and predictions including additional forecasts for cross-biotech collaboration and the significance of digital technologies.